Saniona’s collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research milestone payment to Saniona. The partnership aims to address the cognitive impairments associated with schizophrenia, a critical aspect of the disorder that profoundly affects patients’ daily lives.
Read the article at biostock.se:
https://www.biostock.se/en/2024/10/saniona-achieves-milestone-with-boehringer-ingelheim/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
